First European Genome Network Partner Plans Large Scale Population
Sequencing ProgramBritish Columbia Cancer Agency in Vancouver, CanadaThe Broad Institute in Cambridge, MassachusettsCold Spring Harbor Laboratory in Cold Spring Harbor, New YorkHudsonAlpha Institute for Biotechnology in Huntsville, AlabamaMacrogen & Genomic Medicine Institute in Seoul, KoreaMcGill University in Montreal, CanadaNational Center for Genome Resources in Santa Fe, New Mexico
New York Genome Center in New York, New York
Northwest Genomics Center at University of Washington in Seattle,
WashingtonPeking University in Beijing, China
Takara Bio, Shiga, Japan
Illumina’s FastTrack Services lab in San Diego, California
SAN DIEGO--(BUSINESS WIRE)--
Illumina, Inc. (NASDAQ:ILMN) today announced that Science for Life
Laboratory (SciLifeLab) in Sweden has joined the Illumina Genome Network
(IGN) to provide researchers with broader access to Illumina’s whole
genome sequencing technology. SciLifeLab is the first IGN partner in
Europe and will initiate a national large-scale population sequencing
program seeking to identify genetic causes of human diseases.
“We now have the opportunity to offer an even larger capacity of high
throughput sequencing to researchers from all over Sweden. In the
research program we are about to launch, we aim to sequence more than
1,000 human genomes using the Illumina systems,” said Joakim Lundeberg,
Professor in Gene Technology at KTH Royal Institute of Technology and
Director of the National Genomics Infrastructure at Science for Life
“We are very excited to welcome the SciLifeLab to our prestigious group
of IGN partners and to work with them on their groundbreaking national
genome sequencing project,” said Alex Dickinson, Senior Vice President
Strategic Initiatives for Illumina. “We look forward to working with
SciLifeLab to speed genetic discovery and establish a map of genetic
variability in Sweden.”
IGN links researchers needing large-scale, whole human genome sequencing
with world class institutions that provide this service, and delivers
unmatched access to the highest quality of whole genome sequencing data.
All IGN partners are experienced and well-published using Illumina’s
next-generation sequencing technology, and have completed Illumina’s
Certified Service Provider (CSPro) certification. Each possesses ten or
more Illumina high-throughput sequencing systems, providing the
scalability to handle large sequencing projects with rapid completion
SciLifeLab joins twelve other IGN partners who provide a full range of
For more information about the Illumina Genome Network, please visit http://www.illumina.com/IGN.
is a leading developer, manufacturer, and marketer of life science tools
and integrated systems for the analysis of genetic variation and
function. We provide innovative sequencing and array-based solutions for
genotyping, copy number variation analysis, methylation studies, gene
expression profiling, and low-multiplex analysis of DNA, RNA, and
protein. We also provide tools and services that are fueling advances in
consumer genomics and diagnostics. Our technology and products
accelerate genetic analysis research and its application, paving the way
for molecular medicine and ultimately transforming healthcare.
Science for Life Laboratory (SciLifeLab) is a Swedish national center
for molecular biosciences with focus on health and environmental
research. The center combines frontline technical expertise with
advanced knowledge of translational medicine and molecular bioscience.
SciLifeLab is a joint effort between four Swedish universities
(Karolinska Institutet, KTH Royal Institute of Technology, Stockholm
Universityand Uppsala University).
SciLifeLab was established in 2010 and appointed a national center in
2013 by the Swedish government. More than 200 research groups are
associated with SciLifeLab, which is situated at two nodes in Stockholm
This release may contain forward looking statements that involve risks
and uncertainties. Important factors that could cause actual results to
differ materially from those in any forward-looking statements are
detailed in our filings with the Securities and Exchange Commission,
including our most recent filings on Forms 10-K and 10-Q, or in
information disclosed in public conference calls, the date and time of
which are released beforehand. We do not intend to update any
forward-looking statements after the date of this release.
Source: Illumina, Inc.